Gastrointestinal Cancer Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following Gastrointestinal studies:

A study for patients with metastatic colorectal cancer​

Treatment agent: XL092 and Atezolizumab
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@stjoe.org // 707-521-3830
Study Resources: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer - Full Text View - ClinicalTrials.gov
Sponsor: Exelixus
Location: Providence Cancer Center Santa Rosa, CA

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer (Alliance 221805)

Treatment agent: Duloxetine vs Placebo
Physician: Daniel Mirda, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT04137107
Sponsor: National Cancer Institute (NCI) / Alliance for Clinical Trials in Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer (Alliance 221805)

Treatment agent: Duloxetine vs Placebo
Physician: Yao Yao Pollock, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT04137107
Sponsor: National Cancer Institute (NCI) / Alliance for Clinical Trials in Oncology
Location: Providence Cancer Center Santa Rosa, CA

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects (SWOG S2001)

Treatment agent: Olaparib +/- Pembrolizumab
Physician: Yao Yao Pollock, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT04548752
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center Santa Rosa, CA

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (SWOG S2104)

Treatment agent: Capecitabine and Temozolimide
Physician: Yao Yao Pollock, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://www.clinicaltrials.gov/study/NCT05040360
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center Santa Rosa, CA

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (NRG-GI005 COBRA)​

Treatment agent: Screening: circulating tumor DNA blood test
Physician: Yao Yao Pollock, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT04068103
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
Location: Providence Cancer Center Santa Rosa, CA